Cell and Gene Therapy Clinical Trials Market Size, Share and Growth Outlook, 2026

Cell and Gene Therapy Clinical Trials Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cell and Gene Therapy Clinical Trials Market size is forecast to increase from $16.58 Billion in 2026 to $55.11 Billion in 2034 at a CAGR of 16.2% between 2026 and 2034.

The Cell and Gene Therapy Clinical Trials market report provides detailed analysis and outlook of Cell and Gene Therapy Clinical Trials segments including By Therapy Type (Cell Therapy, Gene Therapy), By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication (Oncology, Genetic Disorders, Musculoskeletal, Rare Diseases, Autoimmune Diseases, Other Indications), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs)) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cell and Gene Therapy Clinical Trials Industry Overview

Clinical Innovation Expanding the Frontiers of Advanced Therapies

The cell and gene therapy clinical trials industry continues to evolve rapidly as researchers explore increasingly sophisticated approaches to treating cancer, genetic disorders, and other complex diseases. Clinical development efforts are expanding beyond traditional gene modification strategies to include engineered immune cells, gene editing technologies, personalized cellular therapies, and advanced receptor-based platforms. At the same time, regulatory agencies are strengthening oversight frameworks to ensure long-term patient safety while supporting continued innovation across the sector.

Enhanced Regulatory Oversight Strengthening Trial Safety Standards

Regulatory authorities are implementing more comprehensive monitoring requirements as advanced therapies progress through clinical development. The U.S. Food and Drug Administration's Center for Biologics Evaluation and Research introduced updated safety protocols governing investigational CAR-T cell therapy trials. The revised framework requires all ongoing and future clinical studies to incorporate standardized long-term molecular monitoring for secondary T-cell malignancies. Additionally, sponsors must perform continuous quantitative real-time polymerase chain reaction tracking of vector integration sites throughout patient follow-up periods. These measures reflect the industry's growing emphasis on long-term safety surveillance and risk management for genetically modified cellular therapies.

CAR-T Clinical Programs Demonstrating Strong Therapeutic Potential

Clinical trial results continue to highlight the effectiveness of engineered cellular therapies in hematologic malignancies. Mustang Bio presented positive updates from its Phase I clinical trial evaluating MB-106, a CD20-targeted CAR-T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The study demonstrated high complete response rates while maintaining a favorable safety profile. Notably, treated patient cohorts experienced no cases of high-grade cytokine release syndrome, one of the most closely monitored adverse events associated with CAR-T therapy. These findings support continued clinical development and reinforce the therapeutic potential of targeted cellular immunotherapies in difficult-to-treat blood cancers.

Engineered TCR Therapies Expanding into Solid Tumor Applications

One of the most significant developments within the cell and gene therapy clinical trials landscape is the growing focus on engineered T-cell receptor therapies for solid tumors. Clinical research presented at the American Society of Clinical Oncology Annual Meeting highlighted promising early-stage results from TCR-engineered T-cell programs targeting intracellular neoantigens in advanced melanoma and synovial sarcoma. Unlike many conventional cellular therapies that have primarily succeeded in hematologic cancers, these engineered TCR approaches are designed to overcome the highly immunosuppressive tumor microenvironments characteristic of solid malignancies. The emerging clinical success of these programs signals an important shift toward broader therapeutic applications for cellular immunotherapy and opens new opportunities for targeting previously challenging cancer indications.

Cell and Gene Therapy Clinical Trials Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cell and Gene Therapy Clinical Trials market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- IQVIA Inc., ICON plc, Labcorp, Thermo Fisher Scientific Inc. (PPD), Syneos Health, Parexel International Corporation, Medpace Holdings, Inc., Novartis AG , Gilead Sciences, Inc. , Bristol Myers Squibb. The Cell and Gene Therapy Clinical Trials market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cell and Gene Therapy Clinical Trials industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cell and Gene Therapy Clinical Trials Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cell and Gene Therapy Clinical Trials companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cell and Gene Therapy Clinical Trials markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cell and Gene Therapy Clinical Trials Market Competitive Benchmarking and Company Analysis

Leading companies in Cell and Gene Therapy Clinical Trials industry include- IQVIA Inc., ICON plc, Labcorp, Thermo Fisher Scientific Inc. (PPD), Syneos Health, Parexel International Corporation, Medpace Holdings, Inc., Novartis AG , Gilead Sciences, Inc. , Bristol Myers Squibb. The Cell and Gene Therapy Clinical Trials market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cell and Gene Therapy Clinical Trials Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cell and Gene Therapy Clinical Trials market remains one of the strongest-performing segments in the country.
The US Cell and Gene Therapy Clinical Trials Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cell and Gene Therapy Clinical Trials market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cell and Gene Therapy Clinical Trials industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cell and Gene Therapy Clinical Trials markets

Canada's strong Cell and Gene Therapy Clinical Trials sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cell and Gene Therapy Clinical Trials market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cell and Gene Therapy Clinical Trials Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cell and Gene Therapy Clinical Trials market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cell and Gene Therapy Clinical Trials population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cell and Gene Therapy Clinical Trials industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cell and Gene Therapy Clinical Trials market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cell and Gene Therapy Clinical Trials sales through 2034

France Cell and Gene Therapy Clinical Trials companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cell and Gene Therapy Clinical Trials Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cell and Gene Therapy Clinical Trials distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cell and Gene Therapy Clinical Trials Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cell and Gene Therapy Clinical Trials market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cell and Gene Therapy Clinical Trials industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cell and Gene Therapy Clinical Trials industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cell and Gene Therapy Clinical Trials Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cell and Gene Therapy Clinical Trials market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cell and Gene Therapy Clinical Trials market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cell and Gene Therapy Clinical Trials Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cell and Gene Therapy Clinical Trials Market Segmentation

By Therapy Type
Cell Therapy
Gene Therapy
By Phase
Phase I
Phase II
Phase III
Phase IV
By Indication
Oncology
Genetic Disorders
Musculoskeletal
Rare Diseases
Autoimmune Diseases
Other Indications
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations (CROs)

Top Companies in Cell and Gene Therapy Clinical Trials Industry

IQVIA Inc.
ICON plc
Labcorp
Thermo Fisher Scientific Inc. (PPD)
Syneos Health
Parexel International Corporation
Medpace Holdings, Inc.
Novartis AG
Gilead Sciences, Inc.
Bristol Myers Squibb

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025